New asthma trials underway

Question:

– Hide quoted text — Show quoted text -> News Item: > Daclizumab (Zenapax) is being investigated as a treatment for asthma. This > drug has been used since 1997 in patients receiving kidney transplants to > prevent rejection.  It is a humanized monoclonal antibody that binds to > receptors on activated T cells, which are directly involved in allergic > inflammatory processes in asthma.  Daclizumab may block processes that lead > to symptoms of asthma. > Does this mean that it may only work on asthmatics whose main problem is > actual IgE-mediated allergies? > That’s not my problem. > My inflammation is caused by air pollution, chronic infection, etc.

That’s my case as well, but I thought that it might be interesting to others here.

Response:

– Hide quoted text — Show quoted text -> News Item: > Daclizumab (Zenapax) is being investigated as a treatment for asthma.  This > drug has been used since 1997 in patients receiving kidney transplants to > prevent rejection.  It is a humanized monoclonal antibody that binds to > receptors on activated T cells, which are directly involved in allergic > inflammatory processes in asthma.  Daclizumab may block processes that lead > to symptoms of asthma. > Does this mean that it may only work on asthmatics whose main problem is > actual IgE-mediated allergies?

Yes.    Lp

Response:

> News Item: > Daclizumab (Zenapax) is being investigated as a treatment for asthma.  This > drug has been used since 1997 in patients receiving kidney transplants to > prevent rejection.  It is a humanized monoclonal antibody that binds to > receptors on activated T cells, which are directly involved in allergic > inflammatory processes in asthma.  Daclizumab may block processes that lead > to symptoms of asthma.

Does this mean that it may only work on asthmatics whose main problem is actual IgE-mediated allergies? That’s not my problem. My inflammation is caused by air pollution, chronic infection, etc. — Steven D. Litvintchouk                  

Response:

>News Item: >Daclizumab (Zenapax) is being investigated as a treatment for asthma.  This >drug has been used since 1997 in patients receiving kidney transplants to >prevent rejection.  It is a humanized monoclonal antibody that binds to >receptors on activated T cells, which are directly involved in allergic >inflammatory processes in asthma.  Daclizumab may block processes that lead >to symptoms of asthma.

ZENAPAX

Related Posts